

Reference number(s)
2141-A, 2680-A

# SPECIALTY GUIDELINE MANAGEMENT

## SOVALDI (sofosbuvir)

### POLICY

#### I. INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

##### FDA-Approved Indications

Sovaldi is indicated for the treatment of:

- Adult patients with chronic hepatitis C virus (HCV) infection as a component of a combination antiviral treatment regimen
  - genotype 1 or 4 infection without cirrhosis or with compensated cirrhosis for use in combination with pegylated interferon and ribavirin
  - genotype 2 or 3 infection without cirrhosis or with compensated cirrhosis for use in combination with ribavirin.
- Chronic HCV genotype 2 or 3 infection in pediatric patients 3 years of age and older without cirrhosis or with compensated cirrhosis for use in combination with ribavirin.

All other indications are considered experimental/investigational and are not medically necessary.

##### Compendial Uses

Hepatitis C genotype 5 or 6 infection (refer to Mavyret SGM)

#### II. CRITERIA FOR INITIAL APPROVAL

##### A. Hepatitis C virus infection, in combination with peginterferon alfa (PEG-IFN) and ribavirin (RBV)

###### 1. Genotype 1 infection

Authorization of up to 12 weeks total may be granted for members who are treatment-naïve.

###### 2. Genotype 4 infection

Authorization of up to 12 weeks total may be granted for members who are treatment-naïve.

##### B. Hepatitis C virus infection, in combination with ribavirin

###### 1. Genotype 1 infection

Authorization of up to 24 weeks total may be granted for members who have documented interferon (IFN) ineligibility (see Section IV).

###### 2. Genotype 2 infection

Authorization of up to 12 weeks total may be granted for members who are treatment-naïve or failed prior treatment with PEG-IFN and RBV.

###### 3. Genotype 3 infection

Authorization of up to 24 weeks total may be granted for members who are treatment-naïve or failed prior treatment with PEG-IFN and RBV.

###### 4. Members with hepatocellular carcinoma awaiting liver transplantation

Reference number(s)
2141-A, 2680-A

Authorization of up to 48 weeks total or until liver transplantation, whichever occurs first, may be granted for members with genotype 1, 2, 3, or 4 infection and hepatocellular carcinoma who meet the MILAN criteria, defined as the following:

- i. Tumor size 5 cm or less in diameter with single hepatocellular carcinomas OR 3 tumor nodules or less, each 3 cm or less in diameter with multiple tumors AND
- ii. No extrahepatic manifestations of the cancer or evidence of vascular invasion of tumor

**C. Hepatitis C virus infection, in combination with Mavyret (with ribavirin)**

Authorization of up to 24 weeks total (as applicable) may be granted for members prescribed Sovaldi in combination with Mavyret (with ribavirin) who meet the criteria for approval for the requested regimen. Refer to the Mavyret SGM for the specific criteria for approval and approval durations.

**D. HCV and HIV coinfection**

Authorization may be granted for members with HCV and HIV coinfection when the criteria for approval of the requested regimen in Section A, B, or C above are met.

**III. CONTINUATION OF THERAPY**

All members (including new members) requesting authorization for continuation of therapy must meet all initial authorization criteria.

**IV. APPENDIX: INTERFERON INELIGIBILITY**

IFN ineligible is defined as one or more of the below:

- Intolerance to IFN
- Autoimmune hepatitis and other autoimmune disorders
- Hypersensitivity to PEG-IFN or any of its components
- Major uncontrolled depressive illness
- A baseline neutrophil count < 1,500/mcL
- A baseline platelet count < 90,000/mcL
- A baseline hemoglobin < 10 g/dL
- History of pre-existing cardiac disease

**V. REFERENCES**

1. Sovaldi [package insert]. Foster City, CA: Gilead Sciences, Inc.; March 2020.
2. AASLD/IDSA/IAS–USA. Recommendations for testing, managing, and treating hepatitis C. <https://www.hcvguidelines.org>. Last changes made December 11, 2019. Accessed August 10, 2020.